KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Biotechnology

Healthcare
$27.00 +0.00%

+$0.00 today

Market cap
$1.44B
Beta
-0.11
P/E (TTM)
-9.9
EPS (TTM)
-$2.74
52W Low $9.83High $27.00

Volume 4.26M

Average 3.47M

KALV Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

KalVista Pharmaceuticals, Inc.NASDAQ: KALV

Weighted Avg Shares (Diluted) · Q4 FY2026 · quarter ended Dec 2025

Weighted avg shares (diluted) of 50.9M shares in Q4 FY2026

Q4 FY2026 weighted avg shares (diluted) was 50.9M shares. Trailing-twelve-month weighted avg shares (diluted) was 52.2M shares.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly weighted avg shares (diluted) holds near 50.9M shares or moves back toward the trailing-twelve-month quarterly average of 13.05M shares.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
50.9M-5.5% QoQ
Last fiscal yearDec 2025
50.9M— YoY
LTMDec 2025
52.2M— YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2026
50.9M USD
Year-over-year change
+2.5%
4-year CAGR
+20.1%

Weighted Avg Shares (Diluted) vs competitors

How KALV compares with its peers on the latest reported figures

  • KALV's LTM Dec 2025 weighted avg shares (diluted) of 52.2M shares is the 9th highest of the 10 companies compared; the peer median is 69.4M shares.
KALV Competitors Peer median
Weighted Avg Shares (Diluted) for KALV and competitors
Company Period LTM YoY 3-year CAGR
GOSSGossamer Bio, Inc.LTM Mar 2026229M -0.3%+39.3%
ADCTADC Therapeutics S.A.LTM Mar 2026138.66M +34.3%+17.6%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 202691.34M +41.8%+29.6%
VSTMVerastem, Inc.LTM Mar 202682.44M +107.0%+62.5%
BCYCBicycle Therapeutics plcLTM Mar 202669.4M +7.1%+32.7%
OMEROmeros CorporationLTM Mar 202662.97M +8.5%+0.4%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 202659.51M +7.9%+21.4%
PRTAProthena Corporation plcLTM Mar 202653.9M -0.4%+4.4%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 202552.2M ——
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202618.96M +6.3%+3.0%
Peer median (excluding KALV) 69.4M+7.9%+21.4%

Competitors are the stored peer set for KALV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
FY2026
Dec 2025
Revenue000073.62M
Cost of Revenue0086.17M06.08M
Gross Profit00(86.17M)067.54M
Gross Margin————91.7%
Research & Development70.17M80.28M86.17M71.71M55.64M
Selling, General & Admin26.45M30.6M54.28M116.29M183.74M
Operating Expenses96.61M110.87M54.28M188M239.38M
Depreciation & Amortization564K718K816K941K1.45M
EBITDA(80.75M)(94.37M)(134.28M)(173.33M)(150.62M)
EBITDA Margin————-204.6%
Operating Income(96.61M)(110.87M)(140.45M)(188M)(171.84M)
Operating Margin————-233.4%
Interest Income1.09M2.23M3.9M6.44M8.68M
Interest Expense0005.79M19.34M
Other Income / Expenses14.27M17.96M5.35M7.94M420K
Income Before Tax(82.34M)(92.91M)(135.1M)(180.05M)(171.42M)
Pre-Tax Margin————-232.9%
Income Tax Expense00(8.45M)3.39M(7.13M)
Net Income(82.34M)(92.91M)(126.64M)(183.44M)(164.29M)
Net Margin————-223.2%
EPS (Basic)(3.36)(3.33)(3.44)(3.69)(3.23)
EPS (Diluted)(3.36)(3.33)(3.44)(3.69)(3.23)
Weighted Avg Shares24.47M27.89M36.79M49.65M50.9M
Weighted Avg Shares (Diluted)24.47M27.89M36.79M49.65M50.9M

KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Intrinsic Alpha fair value

Locked

Current Price

$27.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.